Search This Blog
Friday, July 27, 2018
Alnylam gets Euro panel nod on marketing neuropathy med
Alnylam announced that the Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis, in adults with stage 1 or stage 2 polyneuropathy. If approved by the European Commission, the medicine will be commercialized under the brand name Onpattro. The CHMP positive opinion is based on the evaluation of the effects of patisiran in patients with hATTR amyloidosis and its safety profile as demonstrated in the APOLLO Phase 3 study. The SmPC recommended by the CHMP includes data from APOLLO primary and secondary endpoints, as well as exploratory cardiac endpoints. The European Medicines Agency reviewed patisiran under the accelerated assessment procedure that is granted to medicines that the CHMP believes are of major interest for public health and therapeutic innovation. A CHMP positive opinion is one of the final steps before marketing authorization is granted by the European Commission. The European Commission will now review the CHMP recommendation to deliver its final decision, applicable to all 28 EU member states, plus Iceland, Liechtenstein and Norway. Patisiran is currently under priority review as a Breakthrough Therapy with the U.S. Food and Drug Administration, with an action date of August 11. Regulatory filings in other markets, including Japan, are planned for mid-2018.
https://bit.ly/2LRo7O3
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.